Payment overview · 2025
General Payments
$2,359.42
91 reported records · 19 companies
Healthcare provider profile · identity verified
Robert H Wu, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BOSTON, MA · NPI 1790713824
Verified facts
What the public records show
CMS Open Payments records show Robert H Wu, MD received $2,359.42 in general payments during 2025 across 91 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Paxlovid, Prolia.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 204 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Vemlidy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 272 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $504.12 | 21.4% | 22 | 2025 |
| MERZ NORTH AMERICA, INC. | Unresolved — no canonical attribution shown | $415.98 | 17.6% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $248.73 | 10.5% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $247.35 | 10.5% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $241.32 | 10.2% | 10 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$148.89 | 6.3% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $104.37 | 4.4% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $68.04 | 2.9% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $67.56 | 2.9% | 3 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $67.01 | 2.8% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $61.37 | 2.6% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $37.71 | 1.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $26.86 | 1.1% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $24.65 | 1.0% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $22.77 | 1.0% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $21.94 | 0.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.54 | 0.9% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $14.67 | 0.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.54 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,359.42 | 91 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $323.97 | 13 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $238.01 | 11 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $207.21 | 9 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $184.75 | 8 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $184.65 | 10 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $153.71 | 8 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $130.87 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $82.91 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $75.66 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $68.04 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $67.01 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $63.98 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $63.98 | 3 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $62.70 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $37.71 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $26.86 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $24.65 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $22.77 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $21.94 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $21.04 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $14.67 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.54 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 272 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 204 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 80 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 24 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 31 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
31 | 18 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
204 | 50 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
80 | 17 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
80 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
272 | 39 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1354 | 341 |
| Amlodipine Besylate | Amlodipine Besylate | 1294 | 290 |
| Losartan Potassium | Losartan Potassium | 998 | 263 |
| Metoprolol Succinate | Metoprolol Succinate | 850 | 170 |
| Metformin Hcl | Metformin Hcl | 658 | 168 |
| Simvastatin | Simvastatin | 579 | 137 |
| Diclofenac Sodium | Diclofenac Sodium | 478 | 158 |
| Lisinopril | Lisinopril | 463 | 107 |
| Trazodone Hcl | Trazodone Hcl | 455 | 102 |
| Levothyroxine Sodium | Levothyroxine Sodium | 420 | 76 |
| Omeprazole | Omeprazole | 390 | 109 |
| Tamsulosin Hcl | Tamsulosin Hcl | 361 | 86 |
| Famotidine | Famotidine | 338 | 66 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 331 | 149 |
| Eliquis | Apixaban | 272 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 272 | 112 |
| Mirtazapine | Mirtazapine | 222 | 41 |
| Farxiga | Dapagliflozin Propanediol | 204 | 50 |
| Raloxifene Hcl | Raloxifene Hcl | 200 | 37 |
| Furosemide | Furosemide | 198 | 45 |
| Finasteride | Finasteride | 187 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 186 | 41 |
| Lovastatin | Lovastatin | 181 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 170 | 47 |
| Glipizide Er | Glipizide | 159 | 38 |
| Donepezil Hcl | Donepezil Hcl | 151 | 37 |
| Gabapentin | Gabapentin | 142 | 31 |
| Ammonium Lactate | Ammonium Lactate | 140 | 66 |
| Lidocaine | Lidocaine | 135 | 35 |
| Sertraline Hcl | Sertraline Hcl | 130 | 13 |
| Glipizide | Glipizide | 126 | 23 |
| Alendronate Sodium | Alendronate Sodium | 122 | 31 |
| Baclofen | Baclofen | 119 | 36 |
| Allopurinol | Allopurinol | 114 | 21 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 111 | 17 |
| Atenolol | Atenolol | 108 | 30 |
| Meclizine Hcl | Meclizine Hcl | 105 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 100 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 98 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 96 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 94 | 21 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 93 | 46 |
| Celecoxib | Celecoxib | 88 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 88 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 82 | 26 |
| Valsartan | Valsartan | 82 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 81 | 21 |
| Jardiance | Empagliflozin | 80 | 17 |
| Torsemide | Torsemide | 75 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 23 |
| Hydrocortisone | Hydrocortisone | 71 | 38 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 71 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 71 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 67 | 16 |
| Colchicine | Colchicine | 63 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 16 |
| Trulicity | Dulaglutide | 62 | suppressed |
| Meloxicam | Meloxicam | 61 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | 11 |
| Ciclopirox | Ciclopirox | 60 | 25 |
| Myrbetriq | Mirabegron | 57 | suppressed |
| Methimazole | Methimazole | 54 | suppressed |
| Risperidone | Risperidone | 52 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 51 | 17 |
| Latanoprost | Latanoprost | 50 | 12 |
| Ketoconazole | Ketoconazole | 49 | 18 |
| Estazolam | Estazolam | 48 | suppressed |
| Olanzapine | Olanzapine | 47 | suppressed |
| Tradjenta | Linagliptin | 47 | suppressed |
| Carvedilol | Carvedilol | 46 | suppressed |
| Januvia | Sitagliptin Phosphate | 46 | suppressed |
| Prednisone | Prednisone | 45 | 17 |
| Ezetimibe | Ezetimibe | 44 | suppressed |
| Potassium Chloride | Potassium Chloride | 43 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 41 | 11 |
| Vemlidy | Tenofovir Alafenamide | 41 | suppressed |
| Fenofibrate | Fenofibrate | 40 | suppressed |
| Spironolactone | Spironolactone | 38 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 37 | 21 |
| Entecavir | Entecavir | 36 | suppressed |
| Lorazepam | Lorazepam | 36 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 35 | suppressed |
| Lansoprazole | Lansoprazole | 35 | suppressed |
| Vascepa | Icosapent Ethyl | 34 | suppressed |
| Amoxicillin | Amoxicillin | 33 | 30 |
| Prolia | Denosumab | 31 | 18 |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 27 |
| Irbesartan | Irbesartan | 29 | suppressed |
| Ozempic | Semaglutide | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Acyclovir | Acyclovir | 26 | 13 |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Folic Acid | Folic Acid | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 19 |
| Alprazolam | Alprazolam | 25 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 19 |
| Mupirocin | Mupirocin | 23 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Levemir | Insulin Detemir | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 21 | 11 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 12 |
| Felodipine Er | Felodipine | 19 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 19 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 18 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 17 | 11 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 15 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Restasis | Cyclosporine | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 14 | suppressed |
| Erythromycin | Erythromycin Base | 14 | suppressed |
| Humulin R | Insulin Regular, Human | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Repaglinide | Repaglinide | 14 | suppressed |
| Ssd | Silver Sulfadiazine | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Carbidopa | Carbidopa | 13 | suppressed |
| Cyclosporine | Cyclosporine | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | 11 |
| Nystatin | Nystatin | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Levoxyl | Levothyroxine Sodium | 12 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 12 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 11 | suppressed |
| Hydrocortisone-Acetic Acid | Hydrocortisone/Acetic Acid | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,359.42 · 91 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, Cologuard Collection Kit, DUPIXENT, ELIQUIS, EVENITY, FARXIGA, FFRct, INTELLIS ADAPTIVESTIM, JARDIANCE, LEQVIO, Leqembi, MINIMED 780G, MOUNJARO, NURTEC ODT, OTEZLA, PAXLOVID, PROLIA, REPATHA, REXULTI, REZDIFFRA, SHINGRIX, SMARTVEST, Veozah, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error